New study watches Real-World use of thyroid cancer drugs
NCT ID NCT05733013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is gathering information from 100 adults with a type of thyroid cancer that no longer responds to standard radioactive iodine treatment. Doctors are using special medications called redifferentiating agents to try to make the cancer respond again. The goal is to track how well these drugs work and what side effects occur when they are used in regular medical practice, not just in a research setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOACTIVE IODINE-REFRACTORY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?